News for BriaCell Therapeutics Corp. (BCTXW)

PHILADELPHIA and VANCOUVER, British Columbia, June 04, 2025 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. ( BCTX, BCTXW, BCTXZ), (TSX: BCT) (”œBriaCell”

BriaCell Therapeutics (BCTX) has unveiled significant clinical findings at the 2025 American Society of Clinical Oncology Annual Meeting, showcasing its progres

Bria-OTS has cleared its safety evaluation in the Phase 1/2 study monotherapy dosage settingPhase 1/2 study has now transitioned to dosing patients in combinati

BriaCell Therapeutics (BCTX) has cleared the safety evaluation in its Phase 1/2 monotherapy study for Bria-OTS in metastatic breast cancer. The trial ha

BriaCell Therapeutics (BCTX) has made significant progress in its cancer research efforts as its Bria-OTS treatment has successfully passed a safety assessment

BriaCell Therapeutics (BCTX) is set to present encouraging survival and clinical benefit data through three clinical posters and a publish-only abstract at the

**media[635202]**

PR NewswireVANCOUVER, BC, May 1, 2025 Equity Insider News CommentaryIssued on behalf of Oncolytics Biotech Inc.VANCOUVER, BC, May 1, 2025 /PRNewswire/ -- E

Phase 3 clinical data shows potential predictive biomarkers for treatment response, first identified in Phase 2 studyBiomarkers could be utilized to predict and

BriaCell Therapeutics (BCTX) has unveiled encouraging clinical data from its Phase 3 trial involving Bria-IMT, a treatment aimed at metastatic breast cancer. Th

BriaCell Therapeutics (BCTX) reveals promising Phase 3 data for Bria-IMTâ„¢ in metastatic breast cancer, focusing on predictive biomarkers.

PHILADELPHIA and VANCOUVER, British Columbia, April 28, 2025 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. ( BCTX, BCTXZ) (TSX: BCT) (”œBriaCell” or the

BriaCell (BCTX) Therapeutics has announced encouraging outcomes from its Phase 2 trial of Bria-IMT, a leading candidate in the fight against metastatic breast c

Overall survival and clinical benefit in Phase 2 continue to outperform historical benchmarks, including very heavily pretreated patientsClinical benefit observ

BriaCell Therapeutics Corp. (BCTX) reports positive Phase 2 data for Bria-IMTâ„¢ in metastatic breast cancer. Bria-IMTâ„¢ shows 83% clinical benefit in

Key Takeaways: BriaCell Therapeutics (BCTX) is pricing its public offering at $4.50 per unit, intending to raise around $13.8 million. The offering inclu

Shares of Coursera, Inc. COUR rose sharply in today's pre-market trading after the company reported better-than-expected first-quarter financial results. Cours...

BriaCell Therapeutics (BCTX) will present four clinical data presentations at the ASCO 2025 Annual Meeting in Chicago. The sessions include a Phase III

**media[602837]**